...
【24h】

Clinical value of botulinum toxin in neurological indications.

机译:肉毒杆菌毒素在神经系统适应症中的临床价值。

获取原文
获取原文并翻译 | 示例
           

摘要

Botulinum toxin type-A (BoNT-A) prevents the release of acetylcholine at cholinergic junctions, thereby causing temporary muscle weakness lasting 3-4 months. It is now widely used to treat a broad range of clinical disorders characterized by muscle hyperactivity. BoNT-A has proved effective in the management of several neurological conditions and, in particular, in the management of movement disorders (e.g. blepharospasm, cervical dystonia, laryngeal dystonia, limb dystonia, hemifacial spasm, focal tics, tremor and other hyperkinetic disorders). As a treatment of spasticity, BoNT-A can improve mobility and dexterity as well as preventing the development of distressing and costly secondary complications. In cerebral palsy, BoNT-A is of value, being able to delay or even avoid surgery until motion patterns have become established.
机译:A型肉毒毒素(BoNT-A)阻止胆碱能连接处乙酰胆碱的释放,从而导致暂时性肌肉无力,持续3-4个月。现在,它被广泛用于治疗以肌肉活动亢进为特征的各种临床疾病。事实证明,BoNT-A可有效治疗多种神经系统疾病,特别是可解决运动障碍(例如眼睑痉挛,宫颈肌张力障碍,喉肌张力障碍,肢体肌张力障碍,面肌痉挛,局灶性抽动,震颤和其他运动亢进症)。作为治疗痉挛的方法,BoNT-A可以改善活动能力和灵活性,并防止出现痛苦和代价高昂的继发性并发症。在脑瘫中,BoNT-A具有重要意义,能够延迟甚至避免进行手术,直到形成运动模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号